MYCN and neuroblastoma: Figures 3B–G show that AURKA expression was higher in patients aged 18 months (p < 0.001), MYCN amplified (p < 0.001), stage 4 NB (p < 0.001), COG high risk (p < 0.001), progression (p < 0.001), and dead status (p < 0.001) when compared to the corresponding groups. However, no significant difference was found between the male and female groups (Figure 3A). Supplementary Figure S4 shows a comparison of AURKA expression status in the validation cohort.